


Medisize Holding AG Year-End Results – 2007



Safe Harbour statement

Before we may start with the presentations, we need to remind you that the information made available in this presentation may include forward-looking statements that reflect the intentions, beliefs or current expectations and projections of Medisize Holding AG about the future results of operations, financial condition, liquidity, performance and similar circumstances. Such statements are made on the basis of assumptions and expectations which may prove to be erroneous, although Medisize Holding AG believes them to be reasonable at this time.

Organizational chart



3

Content

- Review Fiscal Year 2007
- Group Financials
- Dental Strategy and Outlook 2008
- Q&A

4

2007 Consolidated Highlights

- 9.8% net sales growth
- 17.1% operating income improvement to CHFm 35.2
- 16.2% net income increase to CHFm 26.3
- EBIT margin increases from 12.0% to 12.8%
- Free cash flow of CHFm 22.9

2007 Consolidated Highlights (2)

- Debt reduced by 25% to CHFm 36.6
- Shareholders' equity grows to CHFm 165.7
- Equity ratio 67% of net assets
- Proposed dividend payment of CHFm 20
- Proposed nominal value reduction of CHFm 23
- Planned capital redemption of CHFm 50

Successful second year for Medisize

Operationally	Accelerated sales growth Margin improvements
Management	Broadened Management band width
Strategy	Sale of Medical narrows strategic focus to pure Dental
Shareholder	Investor friendly dividend policy

7

Strategy

Focus on Dental builds on proven ability to:

- generate strong cash flows
- improve EBIT margins
- innovate
- expand markets
- integrate acquisitions profitably

8

Dental Highlights

- Strengthened the comprehensive product portfolio
- Successfully integrated CEI
- Improved operating efficiency
- Launch of market specific aesthetic dentistry products in Latin America
- Establish subsidiary in China



9

Dental Highlights (2): Markets

- Extraordinary high growth rates in India and China
- Double-digit growth rates in US, Middle East and Eastern Europe
- Good growth in Scandinavia, Baltic region, Switzerland and UK



10

Medical highlights

- Successful implementation of profitability improvement program especially in Airway Management
- Good demand for key products/projects
- Launch of Zephyros breathing machine
- Interesting new development projects in the pipeline
- Production capacity increases
- Reduction of raw material exposure



11

Financial Overview



12

Group Financials

- Financial Results Group, Dental and Medical
- Sale Medical Business
- Distribution Proposal

Medisize Group: Income statement EBIT increase by 17.1%

1'000 CHF	2006	%	2007	%	% YoY
Net Sales	249'864	100.0%	274'233	100.0%	9.8%
Raw materials	82'565	33.0%	88'719	32.4%	7.5%
Personnel expenses	82'921	33.2%	90'149	32.9%	8.7%
Other expenses	44'913	18.0%	50'531	18.4%	12.5%
Depreciation	8'241	3.3%	8'459	3.1%	2.6%
Amortization	1'143	0.5%	1'145	0.4%	0.2%
Total operating expenses	137'218	54.9%	150'284	54.8%	9.5%
EBIT	30'081	12.0%	35'230	12.8%	17.1%

Dental: Income statement

Excellent performance to 16.1% EBIT margin

1'000 CHF	2006	%	2007	%	% YoY
Net Sales	153'560	100.0%	168'110	100.0%	9.5%
Raw materials	42'391	27.6%	46'859	27.9%	10.5%
Personnel expenses	49'793	32.4%	54'163	32.2%	8.8%
Other expenses	32'856	21.4%	35'668	21.2%	8.6%
Depreciation	3'875	2.5%	3'896	2.3%	0.5%
Amortization	347	0.2%	481	0.3%	38.6%
Total operating expenses	86'871	56.6%	94'208	56.0%	8.4%
EBIT	24'298	15.8%	27'043	16.1%	11.3%

15

Medical: Income statement

EBIT increase to traditional level of 9.0%

1'000 CHF	2006	%	2007	%	% YoY
Net Sales	96'310	100.0%	106'122	100.0%	10.2%
Raw materials	40'174	41.7%	41'859	39.4%	4.2%
Personnel expenses	32'709	34.0%	33'978	32.0%	3.9%
Other expenses	12'461	12.9%	15'538	14.6%	24.7%
Depreciation	4'365	4.5%	4'563	4.3%	4.5%
Amortization	796	0.8%	632	0.6%	-20.6%
Total operating expenses	50'331	52.3%	54'711	51.6%	8.7%
EBIT	5'805	6.0%	9'552	9.0%	64.5%

16

Medisize Group: Income statement

Net profit increase by 16.2%

1'000 CHF	2006	%	2007	%	% YoY
EBIT	30'081	12.0%	35'230	12.8%	17.1%
Financial result (net)	-1'150	-0.5%	-1'776	-0.6%	54.4%
Net profit before tax	28'931	11.6%	33'454	12.2%	15.6%
Tax expenses	-6'294	-2.5%	-7'159	-2.6%	13.7%
In % of net profit before tax	21.8%		21.4%		
Net profit	22'637	9.1%	26'295	9.6%	16.2%

17

Medisize Group: Cash flow statement

Free cash flow of 8.3 % of net sales

1'000 CHF	2006	%	2007	%	% YoY
Net profit	22'637		26'295		
Non cash items	17'524		19'245		
Changes in NWC	389		-6'607		
Interest received/paid	-2'809		-2'270		
Income tax paid	-6'383		-7'620		
CF from operations	31'358	12.6%	29'043	10.6%	-7.4%
Purchase of PPE	-5'315		-5'408		
Proceeds form PPE	160		32		
Purchase of FA & IA	-132		-794		
Acquisitions subsidiaries	-590		-9'202		
CF from investments	-5'877		-15'372		
Free cash flow**	26'071	10.4%	22'873	8.3%	-12.3%

* PPE = Property, Plant & Equipment; FA = Financial assets; IA = Intangible assets

** Free cash flow pre acquisitions of subsidiaries

18

Medisize Group: Balance sheet

High equity ratio

1'000 CHF	31.12.06		31.12.07	
Cash & cash equivalents	19'947		13'367	
Receivables	54'248		57'755	
Inventory	49'657		49'846	
Property, plant & equipment	59'101		57'596	
Financial, intangible & tax assets	64'445		69'004	
Total assets	247'398		247'568	
Payables & short term liabilities	30'631		29'186	
Bank loans & other loans	48'499		36'555	
Other long term liabilities	19'072		16'162	
Equity (equity ratio)	149'196	60.3%	165'665	66.9%
Total liabilities & equity	247'398		247'568	
Net financial debt (incl. fin. leasing)	39'015		33'475	

19

Signed Medical sale to Medifiq

Closing expected before end of April 2008

	TCHF
Enterprise selling price (11 times EBIT)	105'000
Cash receipt for consolidated equity of about 40'000 TCHF	75'000
Cash receipt for intercompany loans	27'000

Remarks


Subject to certain adjustments such as net working capital
Third party financial debt assumed by buyer

20

Distribution proposal

	<i>Per share CHF</i>	<i>Total amount TCHF</i>
Dividend April 21, 2008	4.30	20'124
Nominal value reduction July 2008	4.90	22'932
Capital redemption program end of 2008		50'000
Total		93'056

Distribution timetable



Balance Sheet Forecast Positioned for organic growth & acquisitions

1'000 CHF	31.12.07	31.12.08 EST	
Cash & cash equivalents	13'367	7'000	
Other current assets	107'601	71'000	
Non-current assets	126'600	77'000	
Total assets	247'568	155'000	
Other liabilities	45'348	23'000	
Bank loans & other loans	36'555	4'000	
Equity (equity ratio)	165'665	67%	128'000 83%
Total liabilities & equity	247'568	155'000	

23

Dental as a stand-alone Company Strategy and Outlook 2008

Analyst / Media conference
March 19, 2008

24

Agenda – Key Headlines

- **Focus on Dental Business**
- Strengthened Management capacity
- Today's product offering
- Dental market and growth opportunities
- COLTENE growth factors
- COLTENE production sites
- COLTENE dental success factors


Focus on Dental Business

- Name change on Holding level:
Medisize -> COLTENE
- COLTENE is a well-known name in Dental
- All strategy resources and management power on board and executive level are directed to the dental business
- Evaluation of new dental acquisition targets
- The new COLTENE as dental stand alone will continue to generate attractive results

Agenda – Key Headlines

- Focus on Dental Business
- **Strengthened Management capacity**
- Today's product offering
- Dental market and growth opportunities
- COLTENE growth factors
- COLTENE production sites
- COLTENE dental success factors

Strengthened Management




Agenda – Key Headlines

- Focus on dental Business
- Strengthened Management capacity
- **Today's product offering**
- Dental market and growth opportunities
- COLTENE growth factors
- COLTENE production sites
- COLTENE dental success factors

Dental Product World

Adhesives / Restoratives



Dental Product World
Endodontics / Post & Core




Prosthetics / Impression Materials



Dental Product World

Rotary Instruments




Hygiene / Ultrasonic Cleaner




Agenda – Key Headlines

- Focus on Dental Business
- Strengthened Management capacity
- Today's product offering
- **Dental market and growth opportunities**
- COLTENE growth factors
- COLTENE production sites
- COLTENE dental success factors

Global Dental Market



Dental Market – Sales Split




Growth Opportunities

- Global annual growth 3.5% - 4% per year
- Areas
 - Asia >10%
 - Russia / Eastern Europe 7-10%
 - Latin America 5-8%
 - USA and Europe 3%
 - Japan / RoW <3%
- Demographical development and improvement of local economies are driving factors
- Geographical expansion in Emerging Markets is critical for overall growth of the business


Agenda – Key Headlines

- Focus on Dental Business
- Strengthened Management capacity
- Today's product offering
- Dental market and growth opportunities
- **COLTENE growth factors**
- COLTENE production sites
- COLTENE dental success factors

Base for COLTENE Growth Strategy




Growth – Product Innovation




- Goals
 - Launch of 4-6 new products p.a.
 - Innovation cycles actively shortened (3-5 years -> 1-2 years)
 - Balance between internal know-how and external expertise
 - Good leverage of co-operation with universities
 - Capitalize on strong opinion leader network
- COLTENE will stay at the forefront of R&D in dentistry

Growth – Product Innovation




- Prosthetics
 - New products matching implant procedures
 - New features for 3 dimensional scanning and sterilization (silicones)
- Restoration
 - Amalgam replacement filling material
 - Next generation curing light (LED, Laser)
- Endodontics
 - C/W root canal instrument line
 - Cleaning and disinfection system
- Others
 - New polisher line
 - Special products for prevention

Growth – Acquisition




- Focus
 - Complementary product line
 - Growing segments of dental market
 - Specific know-how & technology
 - Traditional and emerging markets
 - Value accretive

Growth – Partnerships



- Existing distribution network
 - Enhanced incentive program based on market share / growth
 - EDI interface and workflow capabilities
 - Branding program for selective products
- Capitalize on additional channels
 - Expand E-Commerce platform
 - Call center with outbound marketing activities
- New partnerships and distributors in local markets
 - i.e. also for bulk filling / packaging / logistics

Growth – Geographical Expansion



- Focus on Emerging Markets
 - Above average growth potential
 - China: COLTENE subsidiary in place today
 - India: subsidiary in place by end of 2008
 - Brazil/Russia: active expansion activities
 - Evaluation of local filling and packaging
- New subsidiaries planned in Europe
 - Southern Europe
 - Eastern Europe

43


COLTENE Global Coverage



- Existing subsidiaries and sales entities
- New resp. planned locations / affiliates

44

Sales Performance Latin America / Far East / Russia



Agenda – Key Headlines

- Focus on Dental Business
- Strengthened Management capacity
- Today's product offering
- Dental market and growth opportunities
- COLTENE growth factors
- **COLTENE production sites**
- COLTENE dental success factors

COLTENE Production sites today



USA



Germany



Switzerland



Hungary



47

Optimal Utilization of Capacity

- COLTENE has state of the art manufacturing environment
- Production sites in Europe and US have capacity to cope with planned growth
- Continuous improvement of margins shown during last couple of years

48

Agenda – Key Headlines

- Focus on Dental Business
- Strengthened Management capacity
- Today's product offering
- Dental market and growth opportunities
- COLTENE growth factors
- COLTENE production sites
- **COLTENE dental success factors**

Dental Key Success Factors

- Fortify brand portfolio and customer loyalty
- Identifying unmet needs of the customers
- Innovate in key growth product ranges with features you can demonstrate
- Provide practical solutions for dental care
- Build on strong long-term relationship with dental distributors world-wide
- Create market-pull via opinion leader network and marketing events


4th Swiss Symposium on esthetic dentistry

4th Swiss Symposium on Esthetic Dentistry
 Stravinsky Auditorium - Montreux
 May 15th - 17th 2008



Currency development

CHF/USD 2007 - 2008



New COLTENE Outlook 2008

Assumptions:

- Dental market consumables sales growth $\geq 3.5\%$
- Forex rate: USD / CHF = 1.10
- Forex rate: EUR / CHF = 1.60

Indications:

- COLTENE Sales CHFm 174
- COLTENE EBIT CHFm 29 (16.7%)

Sales growth rates without forex impact 7.5%



53

**Thank you very much
for your attention!**

Q & A

54